Director, Global Value and Health Economics and Outcomes Research

Jazz Pharmaceuticals • Philadelphia, PA

1d • Remote

About The Position

The Director, Global Value and HEOR is a strategic and execution-oriented leadership role accountable for global and US payer evidence strategy across marketed assets in Jazz Pharmaceuticals’ neurology portfolio. The role aims to maximize brand potential, defend product value, secure expanded access, and generate evidence across the post-launch lifecycle, including label expansions, new formulations, line extensions, and competitive market changes. The Director translates commercial, access, and policy priorities into methodologically sound evidence plans and deliverables, such as updated global core economic models, real-world observational studies, patient registries, Global Value Dossiers (GVDs), and US AMCP dossiers.

The role has both global and regional responsibilities. It serves as the designated US HEOR lead for assigned inline products, partnering with US Market Access, Pricing & Contracting, US Medical Affairs, and the Payer Field Team, while collaborating with EU/INT HEOR colleagues on HTA reassessment strategies and post-launch evidence packages. The Director contributes to Integrated Evidence Generation Plan (IEGP) governance and brand strategy forums, and balances strategic leadership with hands-on technical work, including model development where appropriate.

Responsibilities span lifecycle management and label-expansion evidence strategies; inline value defense and HTA reassessments; US payer evidence and field enablement; advanced health economic modeling; cross-functional evidence governance; publication planning; vendor and budget oversight; and informal mentorship. The position requires translating strategy into rigorous, useful evidence and coordinating delivery across internal teams and external partners.

Requirements

• Master’s degree (MSc, MS, MPH) or PhD in Health Economics, Outcomes Research, Pharmacoeconomics, or a closely related quantitative field.
• At least 7–10 years of experience in HEOR, Global Value, or Health Economics within the biopharmaceutical industry or a top-tier HEOR consulting firm.
• Demonstrated experience leading HEOR strategy and executing evidence deliverables for marketed pharmaceutical products, including lifecycle management, label expansions, and value defense.
• Launch lead for at least two assets as a US HEOR lead, or experience as a country-level HTA lead.
• Extensive experience designing and executing post-marketing HEOR strategies, real-world comparative effectiveness studies, and evidence roadmaps supporting label expansions, line extensions, and value defense.
• Working knowledge of the US managed care landscape, including commercial payers, Medicare Part D/Advantage, Medicaid, PBMs, and integrated delivery networks, and global HTA environments including EU HTA Regulation/JCA, NICE, G-BA, and CADTH.
• Technical expertise building, adapting, and validating economic models, including Markov, partitioned-survival, microsimulation, and dynamic budget-impact models, using clinical trial and real-world data.
• Experience collaborating with US Market Access, Pricing/Contracting, and Payer Field Teams to develop customer-facing tools, interactive budget models, and AMCP dossiers under applicable HCEI communication guidelines.
• Understanding of post-launch evidence challenges in rare diseases, including registry management, natural history benchmarks, long-term surrogate endpoint validation, and specialized HTA reimbursement mechanisms.
• Working knowledge of major US and global health care databases, such as IQVIA, Optum, MarketScan, Medicare SAF, disease-specific registries, and electronic health records, and of epidemiological methods for comparative research.
• Ability to collaborate with regional HEOR teams, particularly EU/INT, on HTA reassessment packages while supporting local market execution.
• Ability to balance evidence strategy with hands-on execution of technical deliverables, including dossiers, models, observational research protocols, and publications.
• Exceptional verbal, written, and presentation skills, with the ability to influence matrix teams without direct authority and defend methodologies before payers, HTA authorities, and scientific reviewers.

Nice To Haves

• Experience with neurology assets.
• Experience serving as the US HEOR lead or driving US pre-launch HEOR deliverables, such as AMCP PIE dossiers, US budget-impact models, and payer field enablement, or significant exposure to these deliverables from a global role.
• Experience conducting post-marketing real-world evidence and patient registry studies and economic evaluations in rare diseases, specialized medicine, or complex chronic conditions.
• Substantial experience collaborating with regional HEOR teams to deliver evidence packages for global HTA reassessments, renewals, or pricing renegotiations.
• A strong peer-reviewed publication record in health economics and outcomes research.
• Preferred product leadership above the country HEOR level.

Responsibilities

• Lead HEOR evidence-generation strategies supporting supplemental regulatory filings for new indications, line extensions, expanded patient populations, and novel delivery formulations or devices.
• Partner with Medical Affairs, Clinical Development, and Biostatistics to incorporate payer-relevant comparative endpoints, patient-reported outcomes, and health-related quality-of-life measures into Phase 3b/4 protocols, pragmatic trials, and expanded access programs.
• Work with Market Access to evaluate evidence requirements across multi-indication lifecycles and deliver comparative effectiveness and economic evidence to support access following label expansions.
• Collaborate on long-term prospective registries, natural history extensions, and post-authorization safety and efficacy studies for rare-disease assets.
• Identify competitive threats, changes in standard of care, and generic or biosimilar erosion; design and execute comparative effectiveness, adherence, and burden-of-illness studies to support product differentiation and access positioning.
• Partner with the EU/INT HEOR team on evidence strategies and analytical packages for HTA reevaluations, conditional reimbursement reviews, and price renegotiations.
• Design real-world data collection programs to fulfill post-launch evidence commitments and support conversion of conditional or temporary reimbursement to permanent access.
• Direct maintenance and updates of Global Value Dossiers, systematic literature reviews, and meta-analyses.
• Serve as the designated US HEOR expert for assigned inline products and translate US brand and access priorities into health economic deliverables.
• Lead authoring, maintenance, and dissemination of AMCP dossiers, unbranded value summaries, and state Medicaid submission dossiers.
• Partner with the US Payer Field Team and US Medical Affairs to develop and train teams on customer-facing economic models and reactive scientific presentations.
• Ensure US HEOR deliverables, economic models, and field materials comply with applicable requirements for communicating health care economic information, including FDAMA Section 114 and the 21st Century Cures Act.
• Collaborate with US Market Access, Pricing, and Contracting to assess value-based agreements and identify measurable real-world endpoints and tracking frameworks using claims or EHR data.
• Monitor US health policy developments and prepare evidence plans and materials relating to ICER and other value-assessment bodies.
• Formulate and execute health economic modeling strategies for marketed products, including cost-effectiveness, cost-utility, budget-impact, and cost-offset models.
• Adapt early models using mature clinical and real-world data, including long-term survival estimates, real-world treatment patterns, adherence, and observational utility weights.
• Use appropriate modeling approaches to address structural uncertainty, treatment sequencing and switching, and heterogeneous rare-disease patient trajectories.
• Build transparent, user-friendly budget-impact models for US commercial, Medicare Advantage, and state Medicaid settings.
• Represent GVHEOR in IEGP governance for inline assets and align post-marketing HEOR studies and budget milestones with brand objectives.
• Partner with Market Access to ensure payer evidence plans validate and update product value stories in response to real-world utilization and payer coverage changes.
• Coordinate with Medical Affairs, Commercial Brand Leads, Regulatory Affairs, Biostatistics, and RWE teams on post-launch evidence initiatives.
• Lead post-marketing HEOR publication planning, manuscript writing and submission, and presentation of data at scientific congresses.
• Manage project budgets and oversee external HEOR consultancies, academic partners, and contract research organizations for quality, timeliness, and budget compliance.
• Provide informal mentorship and technical guidance to associate directors, managers, and fellows across the Evidence and Value Generation department.

Benefits

• Medical insurance
• Dental insurance
• Vision insurance
• 401(k) retirement savings plan
• Flexible paid vacation
• May be eligible for a discretionary annual cash bonus or incentive compensation, depending on the role
• May be eligible for discretionary equity grants

What This Job Offers

• Job Type: Full-time
• Career Level: Director